Monoclonal Antibody to Target CD20 for Non-Hodgkin Lymphoma is under clinical development by Shenzhen Salubris Pharmaceuticals and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for Non-Hodgkin Lymphoma have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Monoclonal Antibody to Target CD20 for Non-Hodgkin Lymphoma’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Monoclonal Antibody to Target CD20 for Non-Hodgkin Lymphoma overview
Monoclonal antibody is under development for the treatment of non-Hodgkin lymphoma. It is a humanized monoclonal antibody which acts by targeting B-lymphocyte antigen CD20.
Shenzhen Salubris Pharmaceuticals overview
Shenzhen Salubris Pharmaceuticals (Salubris) focuses on the research, development, manufacture and distribution of pharmaceutical products. The company’s pipeline products include sacubitril allisartan calcium (S086), allisartan isoproxilamlodipine besylate tablets, allisartan isoproxilindapamide sustained-release tablets, enarodustat (SAL0951), SAL0104, SAL007, SAL003, SAL056P, SAL001, SAL02, fotagliptin, SAL015 and SAL0112, among others. Salubris is investigating small molecules and biological therapeutics for the treatment of metabolic, oncology and also bone diseases. The company also develops interventional medical devices for cardiology, cerebrovascular, structural heart and peripheral vascular disease areas. It operates in the US, Germany, France and Japan. Salubris is headquartered in Shenzhen, Guangdong, China.
For a complete picture of Monoclonal Antibody to Target CD20 for Non-Hodgkin Lymphoma’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
